Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivus Obesity Pill Scores With Phase III Data, But Still Faces Market Hurdles

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With complete Phase III results for its obesity drug Qnexa in hand, Vivus has aced one important test on the road to commercialization. But other major hurdles remain - including passing regulatory muster and convincing a partner to sign up to back a drug that combines generic pills

You may also be interested in...



Arena Airs More Mixed Data For Late-Stage Obesity Drug Lorcaserin

New Phase III data for Arena Pharmaceuticals' novel obesity compound lorcaserin have disappointed the market once again, even though the company is arguing that technically speaking, they will do the trick in satisfying guidelines for FDA approval

Arena Airs More Mixed Data For Late-Stage Obesity Drug Lorcaserin

New Phase III data for Arena Pharmaceuticals' novel obesity compound lorcaserin have disappointed the market once again, even though the company is arguing that technically speaking, they will do the trick in satisfying guidelines for FDA approval

Market Snapshot: Obesity Space Is ‘Not For The Faint of Heart’

Several anti-obesity treatments are in the home stretch of late-stage development, promising to rev up a stagnant market and satisfy pent-up demand. But there's an elephant in the weight loss room - nobody seems to know who will pick up the tab for new drugs

Related Content

Topics

UsernamePublicRestriction

Register

PS004249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel